Increase of CD4+CD25+FoxP3+Regulatory T Cells in Myeloma

被引：0
作者：
Park, Hee Sue [1 ,2 ]
Oh, Suel Gi [1 ]
Son, Bo Ra [1 ,2 ]
Lee, Yong-Pyo [3 ,4 ]
Kwon, Jihyun [3 ,4 ]
机构：
[1] Chungbuk Natl Univ, Dept Lab Med, Coll Med, Cheongju, Chungcheongbugd, South Korea
[2] Chungbuk Natl Univ Hosp, Dept Lab Med, Cheongju, Chungcheongbugd, South Korea
[3] Chungbuk Natl Univ, Dept Internal Med, Coll Med, Cheongju 28644, Chungcheongbugd, South Korea
[4] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, Chungcheongbugd, South Korea
来源：
CLINICAL LABORATORY | 2025年 / 71卷 / 06期
关键词：
flow cytometry; myeloma; regulatory T cells; renal impairment; LENALIDOMIDE; FOXP3;
D O I：
10.7754/Clin.Lab.2024.241208
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Background: In the tumor microenvironment, regulatory T cells (Treg cells), a small subset of CD4+ T cells, can interrupt antitumor immune reactions by interacting with various other immune cells. The present study aimed to determine the expression level of Treg cells in myeloma compared with that in normal control. Methods: Peripheral blood samples from 90 healthy adults and marrow aspiration samples from 13 patients newly diagnosed with myeloma were collected. Eight-color flow cytometry was performed using a Duraclone IM Treg tube kit. A gating strategy was established based on immunophenotypic characteristics of Treg cells identified as CD3+CD4+CD25+FoxP3+CD39+Helios+ cells. Results: A 2.5-fold increase in Treg cells, based on the CD4+CD25+FoxP3+ combination, was confirmed in the initial myeloma diagnosis compared with the normal control. Additionally, increased Treg cells had a weak positive correlation with urine M-protein levels (r = 0.619, p < 0.05). Conclusions: Thus, an increase in Treg cells appears to potentially predict a worse complication of myeloma based on microenvironmental-related biomarkers.
引用
收藏
页码：1143 / 1149
页数：7
相关论文
共 16 条
[1]   Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients [J].
Busch, A. ;
Zeh, D. ;
Janzen, V. ;
Muegge, L. -O. ;
Wolf, D. ;
Fingerhut, L. ;
Hahn-Ast, C. ;
Maurer, O. ;
Brossart, P. ;
von Lilienfeld-Toal, M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 177 (02) :439-453
[2]  
Castillo-Aleman YM, 2022, J Cell Mol Immunol, V1, P5
[3]   Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications [J].
Corso, A ;
Zappasodi, P ;
Pascutto, C ;
Bosoni, T ;
Mangiacavalli, S ;
Lorenzi, A ;
Rusconi, C ;
Lazzarino, M .
ANNALS OF HEMATOLOGY, 2003, 82 (08) :487-491
[4]   Regulatory T cells and treatment of cancer [J].
Curiel, Tyler J. .
CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (02) :241-246
[5]   Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP [J].
Elkord, Eyad ;
Al Samid, May Abd ;
Chaudhary, Belal .
ONCOTARGET, 2015, 6 (24) :20026-20036
[6]   The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells [J].
Galustian, Christine ;
Meyer, Brendan ;
Labarthe, Marie-Christine ;
Dredge, Keith ;
Klaschka, Deborah ;
Henry, Jake ;
Todryk, Stephen ;
Chen, Roger ;
Muller, George ;
Stirling, David ;
Schafer, Peter ;
Bartlett, J. Blake ;
Dalgleish, Angus G. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (07) :1033-1045
[7]   Regulatory T cells in immune-mediated renal disease [J].
Ghali, Joanna R. ;
Wang, Yuan Min ;
Holdsworth, Stephen R. ;
Kitching, A. Richard .
NEPHROLOGY, 2016, 21 (02) :86-96
[8]   Validated Protocol for FoxP3 Reveals Increased Expression in Type 1 Diabetes Patients [J].
Grant, Jean ;
Bourcier, Katarzyna ;
Wallace, Stephen ;
Pan, Dalin ;
Conway, Alexis ;
Seyfert-Margolis, Vicki ;
Wallace, Paul K. .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (02) :69-78
[9]   Frontline therapy for newly diagnosed patients with multiple myeloma [J].
Jung, Sung-Hoon ;
Jo, Jae-Cheol ;
Song, Ga-Young ;
Ahn, Seo-Yeon ;
Yang, Deok-Hwan ;
Ahn, Jae-Sook ;
Kim, Hyeoung-Joon ;
Lee, Je-Jung .
BLOOD RESEARCH, 2020, 55 :37-42
[10]  
Kronenberg K., 2021, Standard protocols for immune profiling of peripheral blood leucocyte subsets by flow cytometry using DuraClone IM reagents
12